Long-term effects of nimodipine on cerebral infarcts and outcome after aneurysmal subarachnoid hemorrhage and surgery


Phase N/A Results

Trial Description

To determine the effect of intravenous nimodipine on delayed ischemic deterioration and computerized tomography (CT)-visualized infarcts after SAH and surgery.


  • Nimodipine (NimotopĀ®)Drug
    Other Names: The treatment group
    Intervention Desc: Calcium channel blocker (L-type calcium channels)

Trial Design

Double-blind, randomized, placebo-controlled trial of 213 patients.

Patient Involvement

Patients were randomized to receive nimodipine (0.5 ug/kg/min) intravenously for 7 to 10 days following SAH and orally (60 mg every four hours) thereafter for a total of 21 days or placebo. Treatment was started immediately after the diagnosis of a ruptured aneurysm had been made and at least 2 hours prior to surgery. Patients were followed for 1 to 3 years.


Type Measure Time Frame Safety Issue
Primary Glasgow Outcome Scale 1 to 3 years post SAH.